Cargando…

Late-onset cblC defect: clinical, biochemical and molecular analysis

BACKGROUND: cblC defect is the most common type of methylmalonic acidemia in China. Patients with late-onset form (>1 year) are often misdiagnosed due to heterogeneous symptoms. This study aimed to describe clinical characteristics and evaluate long-term outcomes of Chinese patients with late-ons...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Si, Ling, Shiying, Liang, Lili, Qiu, Wenjuan, Zhang, Huiwen, Chen, Ting, Zhan, Xia, Xu, Feng, Gu, Xuefan, Han, Lianshu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10536707/
https://www.ncbi.nlm.nih.gov/pubmed/37770946
http://dx.doi.org/10.1186/s13023-023-02890-4
_version_ 1785112934655983616
author Ding, Si
Ling, Shiying
Liang, Lili
Qiu, Wenjuan
Zhang, Huiwen
Chen, Ting
Zhan, Xia
Xu, Feng
Gu, Xuefan
Han, Lianshu
author_facet Ding, Si
Ling, Shiying
Liang, Lili
Qiu, Wenjuan
Zhang, Huiwen
Chen, Ting
Zhan, Xia
Xu, Feng
Gu, Xuefan
Han, Lianshu
author_sort Ding, Si
collection PubMed
description BACKGROUND: cblC defect is the most common type of methylmalonic acidemia in China. Patients with late-onset form (>1 year) are often misdiagnosed due to heterogeneous symptoms. This study aimed to describe clinical characteristics and evaluate long-term outcomes of Chinese patients with late-onset cblC defect. METHODS: A total of 85 patients with late-onset cblC defect were enrolled. Clinical data, including manifestations, metabolites, molecular diagnosis, treatment and outcome, were summarized and analyzed. RESULTS: The age of onset ranged from 2 to 32.8 years old (median age 8.6 years, mean age 9.4 years). The time between first symptoms and diagnosis ranged from a few days to 20 years (median time 2 months, mean time 20.7 months). Neuropsychiatric symptoms were presented as first symptoms in 68.2% of cases, which were observed frequently in schoolchildren or adolescents. Renal involvement and cardiovascular disease were observed in 20% and 8.2% of cases, respectively, which occurred with the highest prevalence in preschool children. Besides the initial symptoms, the disease progressed in most patients and cognitive decline became the most frequent symptom overall. The levels of propionylcarnitine, propionylcarnitine / acetylcarnitine ratio, methylmalonic acid, methylcitric acid and homocysteine, were decreased remarkably after treatment (P<0.001). Twenty-four different mutations of MMACHC were identified in 78 patients, two of which were novel. The c.482G>A variant was the most frequent mutated allele in this cohort (25%). Except for 16 patients who recovered completely, the remaining patients were still left with varying degrees of sequelae in a long-term follow-up. The available data from 76 cases were analyzed by univariate analysis and multivariate logistic regression analysis, and the results showed that the time from onset to diagnosis (OR = 1.025, P = 0. 024) was independent risk factors for poor outcomes. CONCLUSIONS: The diagnosis of late-onset cblC defect is often delayed due to poor awareness of its various and nonspecific symptoms, thus having an adverse effect on the prognosis. It should be considered in patients with unexplained neuropsychiatric and other conditions such as renal involvement, cardiovascular diseases or even multiple organ damage. The c.482G>A variant shows the highest frequency in these patients. Prompt treatment appears to be beneficial. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13023-023-02890-4.
format Online
Article
Text
id pubmed-10536707
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-105367072023-09-29 Late-onset cblC defect: clinical, biochemical and molecular analysis Ding, Si Ling, Shiying Liang, Lili Qiu, Wenjuan Zhang, Huiwen Chen, Ting Zhan, Xia Xu, Feng Gu, Xuefan Han, Lianshu Orphanet J Rare Dis Research BACKGROUND: cblC defect is the most common type of methylmalonic acidemia in China. Patients with late-onset form (>1 year) are often misdiagnosed due to heterogeneous symptoms. This study aimed to describe clinical characteristics and evaluate long-term outcomes of Chinese patients with late-onset cblC defect. METHODS: A total of 85 patients with late-onset cblC defect were enrolled. Clinical data, including manifestations, metabolites, molecular diagnosis, treatment and outcome, were summarized and analyzed. RESULTS: The age of onset ranged from 2 to 32.8 years old (median age 8.6 years, mean age 9.4 years). The time between first symptoms and diagnosis ranged from a few days to 20 years (median time 2 months, mean time 20.7 months). Neuropsychiatric symptoms were presented as first symptoms in 68.2% of cases, which were observed frequently in schoolchildren or adolescents. Renal involvement and cardiovascular disease were observed in 20% and 8.2% of cases, respectively, which occurred with the highest prevalence in preschool children. Besides the initial symptoms, the disease progressed in most patients and cognitive decline became the most frequent symptom overall. The levels of propionylcarnitine, propionylcarnitine / acetylcarnitine ratio, methylmalonic acid, methylcitric acid and homocysteine, were decreased remarkably after treatment (P<0.001). Twenty-four different mutations of MMACHC were identified in 78 patients, two of which were novel. The c.482G>A variant was the most frequent mutated allele in this cohort (25%). Except for 16 patients who recovered completely, the remaining patients were still left with varying degrees of sequelae in a long-term follow-up. The available data from 76 cases were analyzed by univariate analysis and multivariate logistic regression analysis, and the results showed that the time from onset to diagnosis (OR = 1.025, P = 0. 024) was independent risk factors for poor outcomes. CONCLUSIONS: The diagnosis of late-onset cblC defect is often delayed due to poor awareness of its various and nonspecific symptoms, thus having an adverse effect on the prognosis. It should be considered in patients with unexplained neuropsychiatric and other conditions such as renal involvement, cardiovascular diseases or even multiple organ damage. The c.482G>A variant shows the highest frequency in these patients. Prompt treatment appears to be beneficial. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13023-023-02890-4. BioMed Central 2023-09-28 /pmc/articles/PMC10536707/ /pubmed/37770946 http://dx.doi.org/10.1186/s13023-023-02890-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Ding, Si
Ling, Shiying
Liang, Lili
Qiu, Wenjuan
Zhang, Huiwen
Chen, Ting
Zhan, Xia
Xu, Feng
Gu, Xuefan
Han, Lianshu
Late-onset cblC defect: clinical, biochemical and molecular analysis
title Late-onset cblC defect: clinical, biochemical and molecular analysis
title_full Late-onset cblC defect: clinical, biochemical and molecular analysis
title_fullStr Late-onset cblC defect: clinical, biochemical and molecular analysis
title_full_unstemmed Late-onset cblC defect: clinical, biochemical and molecular analysis
title_short Late-onset cblC defect: clinical, biochemical and molecular analysis
title_sort late-onset cblc defect: clinical, biochemical and molecular analysis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10536707/
https://www.ncbi.nlm.nih.gov/pubmed/37770946
http://dx.doi.org/10.1186/s13023-023-02890-4
work_keys_str_mv AT dingsi lateonsetcblcdefectclinicalbiochemicalandmolecularanalysis
AT lingshiying lateonsetcblcdefectclinicalbiochemicalandmolecularanalysis
AT lianglili lateonsetcblcdefectclinicalbiochemicalandmolecularanalysis
AT qiuwenjuan lateonsetcblcdefectclinicalbiochemicalandmolecularanalysis
AT zhanghuiwen lateonsetcblcdefectclinicalbiochemicalandmolecularanalysis
AT chenting lateonsetcblcdefectclinicalbiochemicalandmolecularanalysis
AT zhanxia lateonsetcblcdefectclinicalbiochemicalandmolecularanalysis
AT xufeng lateonsetcblcdefectclinicalbiochemicalandmolecularanalysis
AT guxuefan lateonsetcblcdefectclinicalbiochemicalandmolecularanalysis
AT hanlianshu lateonsetcblcdefectclinicalbiochemicalandmolecularanalysis